Research programme: VLA-4 antagonists - Elan/Wyeth

Drug Profile

Research programme: VLA-4 antagonists - Elan/Wyeth

Alternative Names: Alpha-4 beta-1 integrin antagonists research programme - Elan/Wyeth; Research programme: alpha-4 beta-1 integrin antagonists - Elan/Wyeth; VLA-4 antagonists research programme - Elan/Wyeth

Latest Information Update: 10 Feb 2005

Price : $50

At a glance

  • Originator Elan Corporation
  • Developer Elan Corporation; Wyeth
  • Class Small molecules
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 10 Feb 2005 No development reported - Preclinical for Transplant rejection in USA (unspecified route)
  • 10 Feb 2005 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
  • 10 Feb 2005 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top